India is moving forward with an ambitious plan to expand QR-based traceability across its pharmaceutical industry. Under the initiative, each drug pack will carry a unique QR code linked to a national database, enabling regulators, pharmacists and consumers to verify product authenticity and track the supply chain in real time. The target is full implementation by 2028.

While the goal is laudable enhancing drug-safety, reducing counterfeits and improving recall capabilities critics say the system’s design carries serious vulnerabilities. From the outset, the QR codes themselves offer no built-in cryptographic protection. Experts point out that if the code is simply printed on the box and the database can be accessed with weak authentication, counterfeiters can replicate codes, redirect supply chains or falsify data.

Industry sources familiar with the pilot projects express concern that the backend architecture is fragmented. Multiple regional registries, legacy systems and cloud-hosting providers introduce inconsistencies in data governance and security standards. One digital-security consultant described the system as “a patchwork of portals, each with different login rules and audit trails.”

Another concern: the consumer-verification segment uses generic scanning apps rather than secure dedicated tools. This means that if someone can replicate a QR code, a consumer may still see a “valid” product message even though the pack is counterfeit or diverted. Given India’s high burden of substandard or falsified medicines, such gaps could undermine the policy’s intended impact.

Regulatory officials admit the rollout is being fast-tracked, and while an updated version of the architecture is in development, they acknowledge that “some elements of the legacy registry will remain through the transition.” One senior official said the system’s full encryption layer is scheduled to launch only in 2026. Until then, the rollout may go live with weaker safeguards in place.

Pharmaceutical companies are caught between compliance deadlines and concerns over liability. Smaller manufacturers warn that the cost of compliance printing QR codes, matching each pack to a database, monitoring supply-chain data may fall disproportionately on them, while the larger risk of system breach may harm brand integrity.

As the rollout proceeds, policy-makers face a delicate balance: accelerating deployment to meet patient-safety goals versus ensuring the architecture is robust enough to resist sophisticated attacks. The coming months will test whether India’s traceability ambitions match the security realities of a high-stakes pharmaceutical supply chain.